Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan + CyberKnife SBRT
- Development stage
- Unknown
- Lead developer
- Wake Forest University Health Sciences
- Modality
- Small Molecules
- Administration
- Intravenous, Extracorporeal
01
Overview
This combination therapy regimen consists of low-dose irinotecan administered as a radiosensitizer in conjunction with CyberKnife stereotactic body radiotherapy (SBRT). Developed and investigated by Wake Forest University Health Sciences, the treatment is primarily indicated for patients with colorectal cancer who present with limited liver metastases. Irinotecan, a camptothecin derivative, functions by inhibiting DNA topoisomerase I, which stabilizes the cleavable complex and prevents DNA ligation, ultimately leading to lethal double-strand breaks during SBRT. The CyberKnife system provides image-guided, robotic delivery of high-dose radiation with sub-millimeter precision, allowing for the ablation of liver lesions while minimizing damage to adjacent healthy hepatic tissue.
- Brand names
- CamptosarCyberKnife
- Other names
- Low-dose irinotecan and CyberKnife SBRT
02
Targets
TOP1MT (Mitochondrial topoisomerase I)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on irinotecan + CyberKnife SBRT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan + CyberKnife SBRT.